Sandoz Group is a leading global provider of generic pharmaceuticals and biosimilars, offering a broad portfolio of medicines that span critical therapeutic areas such as oncology, immunology, cardiology, central nervous system disorders and anti-infectives. Through a network of research and development centers, the company focuses on developing high-quality, cost-effective alternatives to branded drugs, including injectables, specialty steriles and biosimilar products that mirror originator biologics. Sandoz’s products are designed to improve patient access to essential medicines while helping healthcare systems manage rising treatment costs.
With roots dating back to 1886, Sandoz traces its heritage to the original Swiss chemical company Sandoz AG, which later merged with Ciba-Geigy to form Novartis in 1996. Today, Sandoz operates as a distinct division within the Novartis portfolio and maintains a presence in more than 100 countries. The company’s global manufacturing network spans Europe, North America, Latin America and Asia, ensuring reliable supply chains and regulatory compliance across diverse markets. Sandoz invests in continuous process innovation to enhance production efficiency and product quality, adhering to stringent international standards set by agencies such as the FDA and EMA.
Under the leadership of Chief Executive Officer Richard Saynor, Sandoz pursues strategic partnerships and licensing agreements to expand its biosimilars pipeline and extend its reach in emerging markets. The management team emphasizes sustainability, digital transformation and patient-centric initiatives, aligning with broader industry trends toward personalized medicine and value-based healthcare. Looking ahead, Sandoz aims to strengthen its competitive position by accelerating development timelines, optimizing its product portfolio and leveraging data analytics to better serve healthcare providers and patients worldwide.
AI Generated. May Contain Errors.
